Omniose
Omniose is an innovative biotechnology company specializing in bioconjugation platforms for vaccine development. Founded in 2016, it leverages proprietary enzyme-based bioconjugation technology to create high-quality vaccines against serious bacterial pathogens, including multidrug-resistant strains. The company collaborates with major industry players like AstraZeneca and has received over $11M in SBIR/STTR grants to fuel its R&D pipeline. Omniose's mission is to develop next-generation vaccines to combat antibiotic resistance and bacterial diseases.
Industries
Nr. of Employees
small (1-50)
Products
Bioconjugate Vaccine Platform
A technology for creating vaccines by enzymatically attaching bacterial polysaccharides to carrier proteins within E. coli cells.
Vaccines against Group B Streptococcus
A vaccine developed using Omniose's platform targeting Group B Streptococcus bacteria.
Vaccines against Klebsiella pneumoniae
A vaccine targeting Klebsiella pneumoniae, developed with Omniose's bioconjugation technology.
Vaccines against Streptococcus pneumoniae
A vaccine created to target Streptococcus pneumoniae using the company's proprietary technology.
Bioconjugate Vaccine Platform
A technology for creating vaccines by enzymatically attaching bacterial polysaccharides to carrier proteins within E. coli cells.
Vaccines against Group B Streptococcus
A vaccine developed using Omniose's platform targeting Group B Streptococcus bacteria.
Vaccines against Klebsiella pneumoniae
A vaccine targeting Klebsiella pneumoniae, developed with Omniose's bioconjugation technology.
Vaccines against Streptococcus pneumoniae
A vaccine created to target Streptococcus pneumoniae using the company's proprietary technology.